Understanding the biological basis for nausea helps patients and providers anticipate, tolerate, and manage this side effect more effectively
However, recurrent severe reactions, spreading rash, or signs of allergic reaction warrant immediate medical evaluation and may require stopping the medication
Safety and when to talk to a clinician GLP-1 and dual incretin medications have important precautions
DOI Scopus21 WoS20 Europe PMC17 2024 McGuinness, A
So in 2014, the FDA began approving these medications for weight loss first Saxenda (liraglutide) , then Wegovy (semaglutide) , Zepbound (tirzepatide) , and most recently, Foundayo (orforglipron)